VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 40 filers reported holding VERONA PHARMA PLC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $54,393 | -14.4% | 3,337 | +11.0% | 0.00% | – |
| Q2 2023 | $63,525 | -41.8% | 3,005 | -44.7% | 0.00% | – |
| Q1 2023 | $109,075 | +0.1% | 5,432 | +30.3% | 0.00% | – |
| Q4 2022 | $108,936 | +1261.7% | 4,169 | +435.9% | 0.00% | – |
| Q3 2022 | $8,000 | +166.7% | 778 | +18.8% | 0.00% | – |
| Q1 2022 | $3,000 | -40.0% | 655 | -25.5% | 0.00% | – |
| Q3 2021 | $5,000 | -58.3% | 879 | -37.5% | 0.00% | – |
| Q1 2021 | $12,000 | 0.0% | 1,407 | -18.3% | 0.00% | – |
| Q4 2020 | $12,000 | +33.3% | 1,723 | +23.4% | 0.00% | – |
| Q3 2020 | $9,000 | -43.8% | 1,396 | -65.1% | 0.00% | – |
| Q1 2020 | $16,000 | -72.4% | 4,000 | -60.2% | 0.00% | – |
| Q4 2019 | $58,000 | +1060.0% | 10,055 | +801.8% | 0.00% | – |
| Q3 2019 | $5,000 | -28.6% | 1,115 | -19.6% | 0.00% | – |
| Q2 2019 | $7,000 | +600.0% | 1,387 | +905.1% | 0.00% | – |
| Q4 2018 | $1,000 | -92.9% | 138 | -80.4% | 0.00% | – |
| Q1 2018 | $14,000 | – | 703 | +70200.0% | 0.00% | – |
| Q4 2017 | $0 | – | 1 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,249,918 | $69,273,663 | 7.59% |
| Aisling Capital Management LP | 1,115,352 | $18,180,238 | 7.49% |
| NEA Management Company, LLC | 5,108,563 | $91,031,474 | 7.03% |
| Octagon Capital Advisors LP | 2,369,000 | $38,614,700 | 5.93% |
| Knoll Capital Management, LLC | 200,000 | $3,260,000 | 3.38% |
| Frazier Life Sciences Management, L.P. | 3,014,349 | $49,133,889 | 3.26% |
| Perceptive Advisors | 4,007,197 | $65,317,311 | 2.18% |
| RA Capital Management | 6,317,990 | $102,983,237 | 2.03% |
| Deep Track Capital, LP | 3,187,415 | $51,954,865 | 2.00% |
| Carlyle Group Inc. | 2,457,500 | $40,008,100 | 1.74% |